MolecularMD

The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.

The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.

Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.

The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.

Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.

The two companies have established a broad framework that will enable them to collaborate on specific projects to develop NGS-based companion diagnostics.

The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.

MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.

The firm's NGS-based Notch 1 mutation detection test will be used to enroll patients in clinical trials.

Pages

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.